Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
2.
Best Pract Res Clin Haematol ; 30(4): 301-305, 2017 12.
Article in English | MEDLINE | ID: mdl-29156199

ABSTRACT

Induction therapy for acute myeloid leukemia has not changed much since 1973, when the 7 + 3 regimen of cytarabine and daunorubicin was born. Since then, various strategies have been evaluated to improve patient response, including dose intensification, the incorporation of additional agents into the regimen, the development of novel agents, and modified approaches for older patients. Recently, two novel agents, CPX-351 and gemtuzumab ozogamicin, have been approved by the US Food and Drug Administration. This review discusses each of the induction strategies and their impact on patient outcomes.


Subject(s)
Aminoglycosides/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Cytarabine/therapeutic use , Daunorubicin/therapeutic use , Induction Chemotherapy/methods , Leukemia, Myeloid, Acute/drug therapy , Aminoglycosides/history , Antibodies, Monoclonal, Humanized/history , Cytarabine/history , Daunorubicin/history , Gemtuzumab , History, 20th Century , History, 21st Century , Humans , Induction Chemotherapy/history , Leukemia, Myeloid, Acute/history
SELECTION OF CITATIONS
SEARCH DETAIL
...